



DISCLOSURE POLICY.

SkinKandy Limited (ACN 636 484 814)

Adopted by the Board on 11 May 2026

1 INTRODUCTION

Under continuous disclosure laws, SkinKandy Limited (ACN 636 484 814) (SkinKandy) must immediately notify the Australian Securities Exchange (ASX) of materially price sensitive information (unless an exception applies). ASX requires that the share market is kept continuously informed of such information.

Failure to notify ASX can be a serious criminal offence, exposing SkinKandy, its managers and directors to imprisonment, fines and damages.

For the purposes of this policy, “SkinKandy Person” has the meaning given to it in SkinKandy’s Securities Trading Policy.

2 CONTINUOUS DISCLOSURE PRINCIPLE

ASX listing rule (LR) 3.1 requires SkinKandy to immediately notify the ASX if it has, or becomes aware of, any information concerning SkinKandy that a reasonable person would expect to have a material effect on the price or value of SkinKandy’s securities were that information to be generally available. This is known as the continuous disclosure obligation.

SkinKandy is also required by section 674 and 674A of the Corporations Act 2001 (Cth) (Corporations Act) to comply with this obligation. In this context, ASX has confirmed in Guidance Note 8 that “immediately” means “promptly and without delay”.

LR 15.7 requires that SkinKandy must not release information that is for release to the market to any person until it has given the information to the ASX and has received acknowledgment that the ASX has released the information to the market.

The continuous disclosure obligation does not apply if the exception to the obligation outlined in section 3 of this policy applies.

Any material price sensitive information must be disclosed to the ASX in accordance with this policy.

When is SkinKandy ‘aware’ of information? Under LR 19.12 (as supported by ASX Guidance Note 8), SkinKandy becomes aware of information if, and as soon as, a director or other officer of SkinKandy has, or ought reasonably to have, come into possession of the information in the course of the performance of their duties as a director or other officer of SkinKandy. An “officer” includes directors, secretaries and senior managers, regardless of their designation. This definition extends not only to information of which SkinKandy’s officers are actually aware, but also information of which they ought reasonably to have been aware. In light of this, ASX Guidance Note 8 recommends that entities have in place appropriate reporting and escalation processes to ensure that information which is potentially market sensitive is promptly brought to the attention of its officers.

Examples of potentially disclosable information. The notes to LR 3.1 give the following non-exhaustive examples of the type of information that, depending on the circumstances, could require disclosure:

- 2.a** a transaction that will lead to a significant change in the nature or scale of SkinKandy's activities;
- 2.b** a material acquisition or disposal of assets or businesses;
- 2.c** the granting or withdrawal of a material licence;
- 2.d** the entry into, variation or termination of a material contract;
- 2.e** a labour dispute or industrial action that may materially impact operations;
- 2.f** a threat, commencement or settlement of material litigation or regulatory action;
- 2.g** earnings that will be materially different from market expectations or from any earnings guidance previously provided;
- 2.h** a change in asset values, liabilities or tax position that is material;
- 2.i** a cybersecurity incident or data breach that is, or may be, price sensitive;
- 2.j** the appointment of a liquidator, administrator or receiver;
- 2.k** an event of default or material breach under a financing facility;
- 2.l** a change in key management personnel (including the appointment or resignation of a CEO, CFO or Chair); or
- 2.m** any other significant development affecting SkinKandy's business, assets or financial condition.

3 EXCEPTION TO THE CONTINUOUS DISCLOSURE PRINCIPLE

3.1 Availability of the exception

Disclosure under LR 3.1 is not required if each of the following is satisfied in relation to the information:

- 3.1.a** the information is confidential and the ASX has not formed the view that the information has ceased to be confidential; and
- 3.1.b** one or more of the following applies:
 - i** it would be a breach of a law to disclose the information;
 - ii** the information concerns an incomplete proposal or negotiation;
 - iii** the information comprises matters of supposition or is insufficiently definite to warrant disclosure;

- iii** preparing (or overseeing the preparation of) external announcements (other than categories of routine announcements that the Committee determines may be prepared and released without its prior review, if any);
 - iv** reviewing and approving proposed external announcements for release to ASX, or, if (d) applies, referring to the Board for approval;
 - v** providing the Board with copies of all material market announcements promptly after they have been made; and
 - vi** maintaining a disclosure register recording:
 - A** all announcements made to ASX;
 - B** all decisions made by the Committee or Board regarding disclosure (including decisions not to disclose and the reasons therefor); and
 - C** all material correspondence with ASX and ASIC in connection with SkinKandy's continuous disclosure obligations.
- 4.c** The Committee should consult with the Board senior management and external advisers as it considers necessary, including where there is doubt as to whether certain information should be disclosed.
- 4.d** If the Chief Executive Officer or the Committee considers that an announcement is of such a nature that it ought to be reviewed and approved by the Board or the Board has directed that the nature of such an announcement requires Board approval, then the Company Secretary should:
- i** take all steps necessary to convene a Board meeting as soon as practicable to consider and approve the announcement; and
 - ii** take such other steps as the Committee determines are necessary to comply with SkinKandy's continuous disclosure obligations, including, if necessary, liaising with ASX to request a trading halt or suspension from trading until the Board is able to meet.
- 4.e** A quorum of the Committee is two members. If a quorum cannot be formed from the Committee members, any officer of SkinKandy may be added as a member of the Committee until a quorum can be formed.

5 REPORTING OBLIGATIONS

- 5.a** Where a continuous disclosure obligation arises, disclosure must not be delayed to accommodate the availability of members of the Committee or, if applicable, the Board. If either the Committee (or, in the case of announcements to be approved by the Board, the Board) is unavailable to make a disclosure decision, the Disclosure Officer must take such other steps as he or she determines are necessary to comply with SkinKandy's continuous disclosure obligations, including, if necessary, liaising with ASX to request a trading halt or suspension from trading until the Committee or the Board is able to meet.
- 5.b** The Disclosure Officer is responsible for ensuring that all Committee or Board decisions that are required to be disclosed to the ASX are dealt with by an appropriate company announcement and that any routine announcement is also accurate, balanced and expressed in a clear and objective manner.
- 5.c** All SkinKandy Persons are required to immediately advise a member of the Committee of any information that they believe may be price sensitive or any issues which could develop into price sensitive information. If a SkinKandy Person has doubt as to whether information concerning SkinKandy is price sensitive, the SkinKandy Person should report that information to a member of the Committee or a Disclosure Officer. He or she should not disclose that information to anyone outside SkinKandy before the ASX is notified.
- 5.d** If any SkinKandy Person becomes aware that:
- i** there may have been inadvertent disclosure of material price sensitive information (which has not yet been disclosed to the ASX) during any communication with external parties; or
 - i** confidential SkinKandy information may have been leaked (whatever its source),

he or she must immediately notify a member of the Committee. The Committee may then determine the appropriate next steps.

6 DISCLOSURE

- 6.a** If the Committee or Board (as applicable) approves the disclosure of information, the Disclosure Officer must immediately lodge that information with the ASX in the manner prescribed by the ASX Listing Rules.
- 6.b** SkinKandy must not release information that is for release to the market to any person until it has given the information to the ASX and has received acknowledgment that the ASX has released the information to the market.
- 6.c** This policy and all information disclosed to the ASX in compliance with this policy will be promptly posted on SkinKandy's corporate website following receipt of such an acknowledgement from the ASX and verification by the Disclosure Officer.

7 TRADING HALTS

- 7.a** In exceptional circumstances, it may be necessary for SkinKandy to request a trading halt to maintain fair, orderly and informed trading in SkinKandy's shares and to manage disclosure issues (for example, if confidential price sensitive information is prematurely or inadvertently disclosed and an immediate release cannot be made).
- 7.b** Subject to the Board's direction, the Committee is responsible for all decisions in relation to trading halts. Unless otherwise provided in section 5 above, only a Disclosure Officer is authorised to request a trading halt and only in accordance with a decision by the Committee or Board (as applicable).

8 FALSE MARKETS

In the event that the Board or any member of the Committee is aware that SkinKandy is relying on an exception to its continuous disclosure obligations, they should notify each other member of the Committee and the Committee may request the Disclosure Officer (or such other person as the Committee thinks fit) to monitor:

- 8.a** the market price of SkinKandy's shares;
- 8.b** major national and local newspapers;
- 8.c** if SkinKandy (or any advisors of SkinKandy working on the particular transaction) has access to them, major news wire services; and
- 8.d** enquiries from analysts or journalists,

for signs that the information to be covered in a potential announcement may have leaked and, if it detects any such signs, to initiate discussions with ASX as soon as practicable.

SkinKandy's general policy is to respond to market rumours or speculation by stating that "SkinKandy does not respond to market rumours or speculation". However, if SkinKandy receives a request from the ASX for information to correct or prevent a false market, a Disclosure Officer must (in consultation with the Committee and external advisers, if necessary) immediately provide that information to the ASX.

9 BRIEFING INVESTORS, ANALYSTS AND THE MEDIA

- 9.a** SkinKandy Persons must ensure that they do not communicate material that a reasonable person would expect would have a material effect on the entity's securities to an external party except where that information has previously been released publicly through the ASX.

- 9.b** Ahead of any new and substantive investor or analyst presentation, a copy of the presentation materials must be released to ASX (even if the information in the presentation would not otherwise require market disclosure).
- 9.c** If any SkinKandy Person participating in a briefing considers that a matter has been raised that might constitute a previously undisclosed material price or value sensitive matter, they must immediately refer the matter to a member of the Committee.
- 9.d** The only people authorised to speak on behalf of SkinKandy to investors, potential investors, analysts or the media are:
- i** the Chair of the Board;
 - ii** the Chief Executive Officer;
 - iii** the Chief Financial Officer; or
 - iv** such other person as determined by the Board.
- 9.e** Authorised spokespersons should clarify information that SkinKandy has released publicly through the ASX but should not comment on material price or value sensitive issues that have not been disclosed to the market generally.
- 9.f** If a question is asked in a briefing which can only be answered by disclosing material price sensitive information which has not been publicly released, the relevant SkinKandy Person should decline to answer the question or take the question on notice.
- 9.g** SkinKandy will observe a Blackout Period (as set out in SkinKandy's Securities Trading Policy). During the Blackout Period, SkinKandy will not hold one-on-one meetings with investors, analysts or media on financial matters.
- 9.i** During the Blackout Period, SkinKandy may respond to requests for background information but will not hold meetings or briefings with individual or institutional investors, analysts or media representatives in relation to financial information, unless the Chief Executive Officer decides that it is appropriate for SkinKandy to do so and the meeting or briefing will be the subject of a specific announcement to the market through the ASX. Only the Chief Executive Officer or Chief Financial Officer may respond to questions from the financial community during Blackout Periods.
- 9.h** All briefing and presentation materials which contain material and price-sensitive information that has not previously been disclosed must be disclosed to the market through the ASX and placed on SkinKandy's corporate website.
- 9.i** Communications from Shareholders will be assessed by management for materiality and relevance. Communications that are considered material, price-sensitive or otherwise appropriate for Board consideration will be escalated to the Board in accordance with this Policy.

10 EARNINGS EXPECTATIONS AND FORECASTS

- 10.a** Comments on expected earnings are confined to SkinKandy's annual and half-year financial reports, the Annual General Meeting of SkinKandy (which would be communicated to the ASX at the time of meeting) and forecasts in a bidder's statement or prospectus.
- 10.b** Any material change in a disclosed earnings expectation must be immediately announced to the ASX before being communicated to anyone outside SkinKandy.
- 10.c** The Chief Financial Officer is responsible for monitoring analyst reports and consensus broker forecasts for SkinKandy to determine whether to raise with the Committee and the Board whether an announcement to the ASX may be necessary to correct factual inaccuracies or historical matters. If the Chief Financial Officer becomes aware of any such inaccuracies or a material divergence between an analyst's or consensus forecast and SkinKandy's own forecasts or earnings expectations, he or she shall liaise with the Committee so that the necessity for an announcement to the ASX and/or trading halt can be considered.
- 10.d** Any correction of factual inaccuracies by SkinKandy does not imply an endorsement of the content of the report or forecast.

11 ANNOUNCEMENT SIGN-OFF PROTOCOL

- 11.a** To facilitate the timely and appropriate release of information, the Board may determine the authorisation procedures for different categories of announcements, which may include tiered approval levels depending on the nature and materiality of the announcement.
- 11.b** The Company Secretary will maintain a record of the Board's authorisation procedures from time to time.

12 YOUR RESPONSIBILITIES

You are expected to ensure that you understand the Disclosure Policy and the impact this has on your areas of responsibility. In particular, you should:

- 12.a** endeavour to comply with the terms of the Disclosure Policy;
- 12.b** undertake all requisite training provided in relation to the matters covered by the Disclosure Policy; and
- 12.c** immediately report any concern, suspected or potential breaches of this Policy to:
 - i the Chief Executive Officer;

- ii the Chief Financial Officer;
- ii the Chair of the Board;
- iv the Chair of the Audit and Risk Committee;
- v any other director of SkinKandy; or
- vi a Whistleblower Protection Officer in accordance with our Whistleblower Protection Policy, which is available on our website.

All material breaches of the Disclosure Policy must be reported immediately to the Board.

13 CONSEQUENCES FOR BREACHING THE DISCLOSURE POLICY

- 13.a** Any suspected breaches of the Disclosure Policy may be thoroughly investigated.
- 13.b** In circumstances where a breach of the Disclosure Policy is established, appropriate disciplinary and remedial actions may be taken.
- 13.c** We reserve the right to inform the appropriate authorities where it is considered that there has been criminal activity or an apparent breach of any law.

14 APPLICATION

This policy applies to all Directors and all employees of SkinKandy, including full-time, part-time and temporary staff, as well as secondees, contractors and affiliates.

15 PERIODIC REVIEW

- 15.a** This policy will be reviewed periodically as required by the Board of Directors (Board) with support from the Audit and Risk Committee to ensure that it is operating effectively and whether any changes are required.
- 15.b** The Board may change this policy from time to time by resolution.

16 OUR VALUES

SkinKandy is committed to setting the standard as industry leaders and being accountable for its actions. This includes following ASX Listing Rules, ASX Guidance and all laws which apply to SkinKandy. SkinKandy understands this involves supporting its team to lead and take accountability through policies like this Disclosure Policy, which educates and details how directors, officers, employees and contractors can help SkinKandy to meet its disclosure

obligations to Government, ASX, Shareholders and the community. For further information on SkinKandy's values, please see its Code of Conduct.

17 OTHER

17.a The Disclosure Policy, Securities Trading Policy and Whistleblower Protection Policy are available on SkinKandy's website.

17.b If you have any questions regarding any aspect of the Disclosure Policy, please contact the Company Secretary.